Advertisement

Renal Cell Carcinoma

  • Inga Peters
  • Maria Gabriel
  • Markus A. Kuczyk
  • Axel S. MerseburgerEmail author
Chapter

Abstract

Renal cell cancer (RCC) accounts for approximately 2–3 % of all human malignancies and shows a worldwide increase of incidence rate of 2 % per year [1]. It primarily affects men and women at the age of 50–70 years with a twofold higher incidence rate in men. Clear cell carcinoma (ccRCC) is the most frequent histological subtype (~80–90 %) besides papillary (10–15 %) and chromophobe (4–5 %) subtype [2]. About 25–30 % of RCC patients present with a metastatic disease (mRCC) at the time of diagnosis. Patients with mRCC generally have a poor prognosis and the 5-year disease-specific survival for University of California Los Angeles integrated staging system (UISS) was 41 % in the low-risk group, 18 % in intermediate and 8 % in the high-risk group [3]. Aetiological risk factors for RCC seem to be smoking, hypertension and obesity [4]. The tumour node metastasis (TNM) staging system and the Fuhrman nuclear grade are commonly recommended for classification, diagnosis and prognosis of RCC patients (Table 39.1).

Keywords

Renal Cell Carcinoma Renal Cell Cancer Tumour Node Metastasis Radical Nephrectomy Clear Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58(3):398–406.PubMedCrossRefGoogle Scholar
  2. 2.
    Bruder E, Passera O, Harms D, Leuschner I, Ladanyi M, Argani P, Eble JN, Struckmann K, Schraml P, Moch H. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol. 2004;28(9):1117–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Bensalah K, Pantuck AJ, Crepel M, Verhoest G, Mejean A, Valeri A, Ficarra V, Pfister C, Ferriere JM, Soulie M, et al. Prognostic variables to predict cancer-related death in incidental renal tumours. BJU Int. 2008;102(10):1376–80.PubMedGoogle Scholar
  4. 4.
    Waalkes S, Rott H, Herrmann TR, Wegener G, Kramer MW, Merseburger AS, Schrader M, Hofmann R, Kuczyk MA, Schrader AJ. Does male sex influence the prognosis of patients with renal cancer? Onkologie. 2011;34(1–2):24–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Raz O, Mendlovic S, Shilo Y, Leibovici D, Sandbank J, Lindner A, Zisman A. Positive surgical margins with renal cell carcinoma have a limited influence on long-term oncological outcomes of nephron sparing surgery. Urology. 2010;75(2):277–80.PubMedCrossRefGoogle Scholar
  6. 6.
    Marszalek M, Meixl H, Polajnar M, Rauchenwald M, Jeschke K, Madersbacher S. Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients. Eur Urol. 2009;55(5):1171–8.PubMedCrossRefGoogle Scholar
  7. 7.
    McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology. 2002;59(6):816–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Waalkes S, Kramer M, Herrmann TR, Schrader AJ, Kuczyk MA, Merseburger AS. Present state of target therapy for disseminated renal cell carcinoma. Immunotherapy. 2010;2(3):393–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Inga Peters
    • 1
  • Maria Gabriel
    • 1
  • Markus A. Kuczyk
    • 1
  • Axel S. Merseburger
    • 1
    Email author
  1. 1.Department of Urology and Urologic OncologyMedizinische Hochschule Hannover (MHH)HannoverGermany

Personalised recommendations